I am a senior management executive and biomedical scientist with 20 years experience in life sciences. Currently, I am Managing Director of Breakpoint Therapeutics GmbH, a VC-funded spin-off company of Evotec that I co-founded. Breakpoint is dedicated to the discovery and development of anti-cancer drugs that target the DNA Damage Response in cancer cells. At Breakpoint, I'm responsible for all corporate matters and operations.Before joining Breakpoint Therapeutics I worked at Evotec with the main aim to facilitate formation of a spin-off company in the area of DNA Damage Responses. This spin-off company is Breakpoint Therapeutics.Prior to Evotec I was an academic researcher, senior lecturer and research group leader in Germany and Australia. My research interests have focused on (1) understanding cellular DNA damage responses at the molecular and genetic level, (2) the discovery of molecular drug targets and new medicines, and (3) the identification and validation of new biomarkers that can predict the success of cancer therapy. A former management consultant with McKinsey & Company, I have also advised several research-related organisations and other institutions on matters of strategic importance and helped my clients grow, change and further develop their unique, individual strengths.I have served on many high-profile boards and committees, including research institute governing boards, grant review and selection panels, conference organising committees, editorial boards of international scientific journals, and the advisory boards of research and music organisations.Advisory, governing & editorial board memberships have included: - Cure Cancer Australia Foundation - Tour de Cure Australia - Cancer Australia - ResearchGATE - German Scholars Organization - Frontiers in Oncology - Mammalian Genome - Heinrich-Pette-Institute - Landesmusikrat Niedersachsen